Ignite Creation Date:
2024-07-17 @ 10:41 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06485466
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2024-06-22
Brief Title:
TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
Sponsor:
Guohui Xu
Organization:
Sichuan Cancer Hospital and Research Institute
Organization Data
Organization:
Sichuan Cancer Hospital and Research Institute
Class:
OTHER
Study ID:
IIT2024041
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Guohui Xu
Lead Sponsor Class:
OTHER
Responsible Party:
Guohui Xu
Responsible Party Title:
Principal Investigator
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Sichuan Cancer Hospital and Research Institute
Old Name:
None
Old Organization:
None